Le NCPI a été rempli au cours du 1er trimestre 2014 par une équipe technique de 17 personnes responsabilisées en sous-groupes pour les parties A, B et UA. Les réponses aux différentes questions se sont référées à celles de NCPI de 2012 pour permettre une meilleure logique. La responsabilit...é générale pour collecter et soumettre les informations requises dans le NCPI partie
more
This document updates the earlier version published in April 2020. In recent weeks, information on the potential use of chloroquine or hydroxychloroquine for the treatment of people with COVID-19 has been disseminated in academic journals and public media. Although there are now ongoing clinical tri...als testing the efficacy and safety of several medicines for COVID-19, as of the date of this document, there is a lack of quality evidence to demonstrate chloroquine and/or hydroxychloroquine are effective in the treatment of COVID-19. Evidence is recently emerging via small studies with sub-optimal methodologies that are conflicting.
more
2010/4 Vol. 22 | pages 425 à 435
ISSN 0995-3914
La reproduction ou représentation de cet article, notamment par photocopie, n'est autorisée que dans les
limites des conditions générales d'utilisation du site ou, le cas échéant, des conditions générales de la
licence souscrite par votr...e établissement. Toute autre reproduction ou représentation, en tout ou partie,
sous quelque forme et de quelque manière que ce soit, est interdite sauf accord préalable et écrit de
l'éditeur, en dehors des cas prévus par la législation en vigueur en France. Il est précisé que son stockage
dans une base de données est également interdit.
more
This Pharmaceutical Country Profile for Kenya (2010) has been developed by the Ministry of Medical Services with support of the World Health Organization. The Profile contains information on existing socio-economic and health-related conditions, resources, regulatory structures and processes and out...comes relating to the pharmaceutical sector in Kenya.
more
The survey is representative of the Union Territory, its states and regions and urban and rural areas. It was conducted in all the districts and in 296 of the 330 townships of Myanmar. A total of 13,730 households were interviewed. It collects data on the occupations of people, how much income they ...earn, and how they use this to meet the food, housing, health, education and other needs of their families. The main focus of the survey is to produce estimates of poverty and living conditions, to provide core data inputs into the System of National Accounts and the Consumer Price Index and to support monitoring of the Sustainable Development Goals.
more
This research report provides results from the study of living conditions
among people with disabilities in Lesotho. Comparisons are made
between disabled and non-disabled in household level and individual
level. Disability was defined as limitation to perform certain activities that
was measure...d according to the Washington City Group questions.
Results obtained in Lesotho are also compared to those obtained in
earlier studies carried out in Mozambique, Zambia, Namibia, Zimbabwe
and Malawi. The Lesotho study was undertaken in 2009-2010.
more
THE REPUBLIC OF BOTSWANA | MINISTRY OF HEALTH | DEPARTMENT OF PUBLIC HEALTH | NATIONAL MALARIA CONTROL PROGRAMME
India AIDS Response Report 2014
Basic Data of Indonesian Community Health Centers as December 2015
Cardiovascular disease (CVD) is the leading cause of global deaths, with the majority occurring in low- and middle-income countries (LMIC). The primary and secondary prevention of CVD is suboptimal throughout the world, but the evidence-practice gaps are much more pronounced in LMIC. Barriers at the... patient, health-care provider, and health system level prevent the implementation of optimal primary and secondary prevention. Identification of the particular barriers that exist in resource-constrained settings is necessary to inform effective strategies to reduce the identified evidence-practice gaps. Furthermore, targeting modifiable factors that contribute most significantly to the global burden of CVD, including tobacco use, hypertension, and secondary prevention for CVD will lead to the biggest gains in mortality reduction. We review a select number of novel, resource-efficient strategies to reduce premature mortality from CVD, including: (1) effective measures for tobacco control; (2) implementation of simplified screening and management algorithms for those with or at risk of CVD, (3) increasing the availability and affordability of simplified and cost-effective treatment regimens including combination CVD preventive drug therapy, and (4) simplified delivery of health care through task-sharing (non-physician health workers) and optimizing self-management (treatment supporters). Developing and deploying systems of care that address barriers related to the above, will lead to substantial reductions in CVD and related mortality.
more